ABSTRACT
Unsolved Mendelian cases often lack obvious pathogenic coding variants, suggesting potential non-coding etiologies. Here, we present a single cell multi-omic framework integrating embryonic mouse chromatin accessibility, histone modification, and gene expression assays to discover cranial motor neuron (cMN) cis-regulatory elements and subsequently nominate candidate non-coding variants in the congenital cranial dysinnervation disorders (CCDDs), a set of Mendelian disorders altering cMN development. We generated single cell epigenomic profiles for ∼86,000 cMNs and related cell types, identifying ∼250,000 accessible regulatory elements with cognate gene predictions for ∼145,000 putative enhancers. Seventy-five percent of elements (44 of 59) validated in an in vivo transgenic reporter assay, demonstrating that single cell accessibility is a strong predictor of enhancer activity. Applying our cMN atlas to 899 whole genome sequences from 270 genetically unsolved CCDD pedigrees, we achieved significant reduction in our variant search space and nominated candidate variants predicted to regulate known CCDD disease genes MAFB, PHOX2A, CHN1, and EBF3 – as well as new candidates in recurrently mutated enhancers through peak- and gene-centric allelic aggregation. This work provides novel non-coding variant discoveries of relevance to CCDDs and a generalizable framework for nominating non-coding variants of potentially high functional impact in other Mendelian disorders.
Competing Interest Statement
D.G.M. is a paid advisor to GlaxoSmithKline, Insitro, and Overtone Therapeutics, and has received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Google, Merck, Microsoft, Pfizer, and Sanofi-Genzyme. M.E.T. has received research support and/or reagents from Microsoft, Illumina Inc, Pacific Biosciences, and Ionis Pharmaceuticals.
Funding Statement
The work was supported by the Gabriella Miller Kids First Pediatric Research Program NHBLI X01HL132377 (E.C.E.), NEI R01EY027421 (D.G.M., M.E.T., E.C.E.), NICHD R01HD114353 (L.A.P), NHGRI R01HG003988 (L.A.P.), NIMH R01MH115957 (M.E.T., H.B.), DP2-AG072437 (E.A.L.), NINDS K08-NS099502 (M.F.R.), NHLBI T32-HL007627 (M.F.R), NIGMS T32-GM007748 (M.F.R.), Project ALS A13-0416 (E.C.E.), Boston Children's Hospital - Broad Institute Collaborative Grant (E.C.E.), Boston Children's Hospital Manton Center Rare Disease Fellowships (A.S.L, B.Z.) and Manton Center Pilot Project Award (B.Z.), Suh Kyungbae Foundation (E.A.L.), the Abramson Fund for Undergraduate Research (C.L.), and the Boston Children's Hospital Intellectual and Developmental Disabilities Research Center (NIH U54HD090255). The research of M.K. and L.A.P. was conducted at the E.O. Lawrence Berkeley National Laboratory and performed under U.S. Department of Energy Contract DE-AC02-05CH11231, University of California. E.C.E. is an Investigator of the Howard Hughes Medical Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Boston Children's Hospital gave ethical approval for this work (clinicaltrials.gov identifier NCT03059420).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All data generated in this work are available through the Gene Expression Omnibus accession number GSExxxxxx.
